Comprehensive Analysis Reveals USP45 as a Novel Putative Oncogene in Pan-Cancer
Background: Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of target proteins and playing an important role in tumor. However, the mechanism of deubiquitinating enzyme USP45 in tumors remains unclear. Method...
Saved in:
Published in | Frontiers in molecular biosciences Vol. 9; p. 886904 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
28.06.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 2296-889X 2296-889X |
DOI | 10.3389/fmolb.2022.886904 |
Cover
Loading…
Abstract | Background:
Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of target proteins and playing an important role in tumor. However, the mechanism of deubiquitinating enzyme USP45 in tumors remains unclear.
Methods:
Based on the RNA-seq data of tissues and cell lines in The Cancer Genome Atlas (TCGA) database, GTEx and CCLE database, the pan-cancer analysis of USP45 expression and survival outcome were performed using R software and Kaplan-Meier Plotter. The structural variants, gene mutations and gene copy number alteration of USP45 were analyzed using the TCGA Pan-Cancer Atlas Studies dataset in the cBioPortal database. The relationships between USP45 and mRNA methylation, tumor heterogeneity, tumor stemness, and tumor immunity were performed by Sangerbox platform and TIMER2.0 using Pearson correlation analysis. Through the ENCORI database and string database, we constructed the ceRNA regulatory mechanism and protein-protein interaction network for USP45. Based on the RNA-seq data in TCGA and GTEx databases, we also constructed the downstream regulatory network for USP45 using the Limma and ClusterProfiler packages of R software. At last, the protein expression levels of USP45 were detected by immunohistochemistry in tumor tissue microarrays.
Results:
USP45 is upregulated in most types of tumors and negatively correlated with the overall survival and recurrence-free survival of patient. Furthermore, the structural variation, gene mutations and gene copy number variation of USP45 were identified in different types of tumors. The pan-cancer analysis showed that USP45 was closely related to mRNA methylation, tumor heterogeneity and tumor stemness. In most types of tumors, the expression of USP45 was positively correlated with many immune checkpoint molecules and immune regulators such as PD-L1, while negatively correlated with the infiltration levels of NK cells, Th1 cells, macrophages, and dendritic cells in the tumor microenvironment. Finally, we constructed the ceRNA regulatory network, protein-protein interaction network and downstream regulatory network for USP45 in different types of tumors.
Conclusion:
Our study firstly explored the putative oncogenic role of USP45 in pan-cancer, and provided insights for further investigation of USP45. |
---|---|
AbstractList | Background: Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of target proteins and playing an important role in tumor. However, the mechanism of deubiquitinating enzyme USP45 in tumors remains unclear.Methods: Based on the RNA-seq data of tissues and cell lines in The Cancer Genome Atlas (TCGA) database, GTEx and CCLE database, the pan-cancer analysis of USP45 expression and survival outcome were performed using R software and Kaplan-Meier Plotter. The structural variants, gene mutations and gene copy number alteration of USP45 were analyzed using the TCGA Pan-Cancer Atlas Studies dataset in the cBioPortal database. The relationships between USP45 and mRNA methylation, tumor heterogeneity, tumor stemness, and tumor immunity were performed by Sangerbox platform and TIMER2.0 using Pearson correlation analysis. Through the ENCORI database and string database, we constructed the ceRNA regulatory mechanism and protein-protein interaction network for USP45. Based on the RNA-seq data in TCGA and GTEx databases, we also constructed the downstream regulatory network for USP45 using the Limma and ClusterProfiler packages of R software. At last, the protein expression levels of USP45 were detected by immunohistochemistry in tumor tissue microarrays.Results: USP45 is upregulated in most types of tumors and negatively correlated with the overall survival and recurrence-free survival of patient. Furthermore, the structural variation, gene mutations and gene copy number variation of USP45 were identified in different types of tumors. The pan-cancer analysis showed that USP45 was closely related to mRNA methylation, tumor heterogeneity and tumor stemness. In most types of tumors, the expression of USP45 was positively correlated with many immune checkpoint molecules and immune regulators such as PD-L1, while negatively correlated with the infiltration levels of NK cells, Th1 cells, macrophages, and dendritic cells in the tumor microenvironment. Finally, we constructed the ceRNA regulatory network, protein-protein interaction network and downstream regulatory network for USP45 in different types of tumors.Conclusion: Our study firstly explored the putative oncogenic role of USP45 in pan-cancer, and provided insights for further investigation of USP45. Background: Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of target proteins and playing an important role in tumor. However, the mechanism of deubiquitinating enzyme USP45 in tumors remains unclear. Methods: Based on the RNA-seq data of tissues and cell lines in The Cancer Genome Atlas (TCGA) database, GTEx and CCLE database, the pan-cancer analysis of USP45 expression and survival outcome were performed using R software and Kaplan-Meier Plotter. The structural variants, gene mutations and gene copy number alteration of USP45 were analyzed using the TCGA Pan-Cancer Atlas Studies dataset in the cBioPortal database. The relationships between USP45 and mRNA methylation, tumor heterogeneity, tumor stemness, and tumor immunity were performed by Sangerbox platform and TIMER2.0 using Pearson correlation analysis. Through the ENCORI database and string database, we constructed the ceRNA regulatory mechanism and protein-protein interaction network for USP45. Based on the RNA-seq data in TCGA and GTEx databases, we also constructed the downstream regulatory network for USP45 using the Limma and ClusterProfiler packages of R software. At last, the protein expression levels of USP45 were detected by immunohistochemistry in tumor tissue microarrays. Results: USP45 is upregulated in most types of tumors and negatively correlated with the overall survival and recurrence-free survival of patient. Furthermore, the structural variation, gene mutations and gene copy number variation of USP45 were identified in different types of tumors. The pan-cancer analysis showed that USP45 was closely related to mRNA methylation, tumor heterogeneity and tumor stemness. In most types of tumors, the expression of USP45 was positively correlated with many immune checkpoint molecules and immune regulators such as PD-L1, while negatively correlated with the infiltration levels of NK cells, Th1 cells, macrophages, and dendritic cells in the tumor microenvironment. Finally, we constructed the ceRNA regulatory network, protein-protein interaction network and downstream regulatory network for USP45 in different types of tumors. Conclusion: Our study firstly explored the putative oncogenic role of USP45 in pan-cancer, and provided insights for further investigation of USP45. Background: Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of target proteins and playing an important role in tumor. However, the mechanism of deubiquitinating enzyme USP45 in tumors remains unclear. Methods: Based on the RNA-seq data of tissues and cell lines in The Cancer Genome Atlas (TCGA) database, GTEx and CCLE database, the pan-cancer analysis of USP45 expression and survival outcome were performed using R software and Kaplan-Meier Plotter. The structural variants, gene mutations and gene copy number alteration of USP45 were analyzed using the TCGA Pan-Cancer Atlas Studies dataset in the cBioPortal database. The relationships between USP45 and mRNA methylation, tumor heterogeneity, tumor stemness, and tumor immunity were performed by Sangerbox platform and TIMER2.0 using Pearson correlation analysis. Through the ENCORI database and string database, we constructed the ceRNA regulatory mechanism and protein-protein interaction network for USP45. Based on the RNA-seq data in TCGA and GTEx databases, we also constructed the downstream regulatory network for USP45 using the Limma and ClusterProfiler packages of R software. At last, the protein expression levels of USP45 were detected by immunohistochemistry in tumor tissue microarrays. Results: USP45 is upregulated in most types of tumors and negatively correlated with the overall survival and recurrence-free survival of patient. Furthermore, the structural variation, gene mutations and gene copy number variation of USP45 were identified in different types of tumors. The pan-cancer analysis showed that USP45 was closely related to mRNA methylation, tumor heterogeneity and tumor stemness. In most types of tumors, the expression of USP45 was positively correlated with many immune checkpoint molecules and immune regulators such as PD-L1, while negatively correlated with the infiltration levels of NK cells, Th1 cells, macrophages, and dendritic cells in the tumor microenvironment. Finally, we constructed the ceRNA regulatory network, protein-protein interaction network and downstream regulatory network for USP45 in different types of tumors. Conclusion: Our study firstly explored the putative oncogenic role of USP45 in pan-cancer, and provided insights for further investigation of USP45.Background: Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of target proteins and playing an important role in tumor. However, the mechanism of deubiquitinating enzyme USP45 in tumors remains unclear. Methods: Based on the RNA-seq data of tissues and cell lines in The Cancer Genome Atlas (TCGA) database, GTEx and CCLE database, the pan-cancer analysis of USP45 expression and survival outcome were performed using R software and Kaplan-Meier Plotter. The structural variants, gene mutations and gene copy number alteration of USP45 were analyzed using the TCGA Pan-Cancer Atlas Studies dataset in the cBioPortal database. The relationships between USP45 and mRNA methylation, tumor heterogeneity, tumor stemness, and tumor immunity were performed by Sangerbox platform and TIMER2.0 using Pearson correlation analysis. Through the ENCORI database and string database, we constructed the ceRNA regulatory mechanism and protein-protein interaction network for USP45. Based on the RNA-seq data in TCGA and GTEx databases, we also constructed the downstream regulatory network for USP45 using the Limma and ClusterProfiler packages of R software. At last, the protein expression levels of USP45 were detected by immunohistochemistry in tumor tissue microarrays. Results: USP45 is upregulated in most types of tumors and negatively correlated with the overall survival and recurrence-free survival of patient. Furthermore, the structural variation, gene mutations and gene copy number variation of USP45 were identified in different types of tumors. The pan-cancer analysis showed that USP45 was closely related to mRNA methylation, tumor heterogeneity and tumor stemness. In most types of tumors, the expression of USP45 was positively correlated with many immune checkpoint molecules and immune regulators such as PD-L1, while negatively correlated with the infiltration levels of NK cells, Th1 cells, macrophages, and dendritic cells in the tumor microenvironment. Finally, we constructed the ceRNA regulatory network, protein-protein interaction network and downstream regulatory network for USP45 in different types of tumors. Conclusion: Our study firstly explored the putative oncogenic role of USP45 in pan-cancer, and provided insights for further investigation of USP45. |
Author | Li, Kai Bian, Hua Wang, Qian Gong, Pengju Chen, Zhiguo He, Haifa Zhao, Xulin |
AuthorAffiliation | 1 Zhang Zhongjing College of Chinese Medicine , Nanyang Institute of Technology , Nanyang , China 2 Henan Key Laboratory of Zhang Zhongjing Formulae and Herbs for Immunoregulation , Nanyang Institute of Technology , Nanyang , China 3 School of Basic Medical Sciences , Xinxiang Medical University , Xinxiang , China 4 Department of Pathology , Central Hospital of Nanyang City , Nanyang , China 6 The University of Texas MD Anderson Cancer Center UThealth Graduate School of Biomedical Sciences , Houston , TX , United States 5 Department of Oncology , The First People’s Hospital of Nanyang , Nanyang , China |
AuthorAffiliation_xml | – name: 3 School of Basic Medical Sciences , Xinxiang Medical University , Xinxiang , China – name: 5 Department of Oncology , The First People’s Hospital of Nanyang , Nanyang , China – name: 1 Zhang Zhongjing College of Chinese Medicine , Nanyang Institute of Technology , Nanyang , China – name: 6 The University of Texas MD Anderson Cancer Center UThealth Graduate School of Biomedical Sciences , Houston , TX , United States – name: 2 Henan Key Laboratory of Zhang Zhongjing Formulae and Herbs for Immunoregulation , Nanyang Institute of Technology , Nanyang , China – name: 4 Department of Pathology , Central Hospital of Nanyang City , Nanyang , China |
Author_xml | – sequence: 1 givenname: Kai surname: Li fullname: Li, Kai – sequence: 2 givenname: Qian surname: Wang fullname: Wang, Qian – sequence: 3 givenname: Hua surname: Bian fullname: Bian, Hua – sequence: 4 givenname: Zhiguo surname: Chen fullname: Chen, Zhiguo – sequence: 5 givenname: Haifa surname: He fullname: He, Haifa – sequence: 6 givenname: Xulin surname: Zhao fullname: Zhao, Xulin – sequence: 7 givenname: Pengju surname: Gong fullname: Gong, Pengju |
BookMark | eNp9kUtr3DAURkVJaB7ND-jOy248kfWwpE0hDH0EQmfIA7oT1_L1RMGWppJnIP--diaUpouurrj6viPBOSNHIQYk5GNFF5xrc9kNsW8WjDK20Lo2VLwjp4yZutTa_Dz663xCLnJ-opRWknJVi_fkhEvNa8P5KVkt47BN-Igh-z0WVwH65-xzcYt7hD4XD3drIQvIBRQ_4h77Yr0bYZyjq-DiBgMWPhRrCOUSgsP0gRx3Uw8vXuc5efj65X75vbxZfbteXt2UTgg2lkyqjhunG82ZBKUldK6mVErVTtNoDpWSrWaO605LLbSWCiSjbVU306bl5-T6wG0jPNlt8gOkZxvB25dFTBsLafSuR0uxE8K1rpuIQgMDjpU0rWoUUGqAT6zPB9Z21wzYOgxjgv4N9O1N8I92E_fWMMVNxSbAp1dAir92mEc7-Oyw7yFg3GXLalNRoTSjU7Q6RF2KOSfs_jxTUTt7tS9e7ezVHrxOHfVPx_lZQpx_4_v_NH8D9A2o6Q |
CitedBy_id | crossref_primary_10_2147_DDDT_S478388 crossref_primary_10_18632_aging_205149 crossref_primary_10_3390_cells12121585 crossref_primary_10_1083_jcb_202407014 crossref_primary_10_2147_JIR_S403928 crossref_primary_10_3390_ijms25084440 |
Cites_doi | 10.1038/s41571-020-00460-2 10.1155/2021/4061525 10.1016/j.bbadis.2019.02.019 10.1158/1078-0432.CCR-20-3054 10.1186/s12943-022-01500-4 10.1080/10409238.2018.1447542 10.1042/BCJ20160762 10.3390/ijms222111971 10.1016/j.ejphar.2019.01.004 10.3390/ijms21228855 10.1136/jmedgenet-2018-105709 10.1038/s41598-018-32685-8 10.1016/j.cell.2018.03.034 10.1016/j.molonc.2015.06.006 10.1007/s10585-022-10146-x 10.1016/j.bbamcr.2012.04.011 10.3748/wjg.v27.i21.2710 10.1111/bpa.12670 10.1158/1078-0432.CCR-16-2598 10.1016/j.cell.2009.04.042 10.1097/00001622-200201000-00012 10.1016/j.pharmthera.2018.04.004 10.4161/cbt.25329 10.1136/jmedgenet-2015-103334 10.1007/s00281-015-0486-4 10.1016/j.canlet.2019.11.009 10.1038/s41467-020-16142-7 10.1038/nature24451 10.1016/j.bbcan.2021.188609 10.1016/j.cell.2017.01.018 10.1007/978-1-4939-3756-1_3 10.21037/atm.2020.02.136 10.1016/j.ccell.2019.06.009 10.3390/ijms22030986 10.1186/s12964-020-00612-y 10.1038/sj.emboj.7601567 10.1186/s12943-019-1055-6 10.1038/onc.2014.327 10.15252/embj.201489184 10.1016/j.molcel.2021.10.027 10.1016/j.redox.2021.102194 10.1038/s41423-020-0488-6 10.1038/s41388-019-1145-3 10.1158/2326-6066.CIR-18-0910 10.1002/cam4.1675 10.1093/jnci/djy085 |
ContentType | Journal Article |
Copyright | Copyright © 2022 Li, Wang, Bian, Chen, He, Zhao and Gong. Copyright © 2022 Li, Wang, Bian, Chen, He, Zhao and Gong. 2022 Li, Wang, Bian, Chen, He, Zhao and Gong |
Copyright_xml | – notice: Copyright © 2022 Li, Wang, Bian, Chen, He, Zhao and Gong. – notice: Copyright © 2022 Li, Wang, Bian, Chen, He, Zhao and Gong. 2022 Li, Wang, Bian, Chen, He, Zhao and Gong |
DBID | AAYXX CITATION 7X8 5PM DOA |
DOI | 10.3389/fmolb.2022.886904 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
DocumentTitleAlternate | Li et al |
EISSN | 2296-889X |
ExternalDocumentID | oai_doaj_org_article_0ef44cdcf75d48a2a3e159d7b7a009a3 PMC9273912 10_3389_fmolb_2022_886904 |
GrantInformation_xml | – fundername: ; grantid: 202300410019 – fundername: ; grantid: 82002592 |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAYXX ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION GROUPED_DOAJ HYE KQ8 M48 M~E OK1 PGMZT RPM 7X8 5PM |
ID | FETCH-LOGICAL-c442t-257f39c8b8325a785afc600557dc60983a175d82c38f85848857a520d16b8f8d3 |
IEDL.DBID | DOA |
ISSN | 2296-889X |
IngestDate | Wed Aug 27 01:30:45 EDT 2025 Thu Aug 21 18:15:40 EDT 2025 Fri Jul 11 16:27:18 EDT 2025 Tue Jul 01 02:15:26 EDT 2025 Thu Apr 24 23:02:43 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c442t-257f39c8b8325a785afc600557dc60983a175d82c38f85848857a520d16b8f8d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors have contributed equally to this work Reviewed by: Chih-Yang Wang, Taipei Medical University, Taiwan Edited by: Xin Zhang, Jiangmen Central Hospital, China Urminder Singh, Iowa State University, United States This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences |
OpenAccessLink | https://doaj.org/article/0ef44cdcf75d48a2a3e159d7b7a009a3 |
PMID | 35836933 |
PQID | 2691047820 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_0ef44cdcf75d48a2a3e159d7b7a009a3 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9273912 proquest_miscellaneous_2691047820 crossref_primary_10_3389_fmolb_2022_886904 crossref_citationtrail_10_3389_fmolb_2022_886904 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-06-28 |
PublicationDateYYYYMMDD | 2022-06-28 |
PublicationDate_xml | – month: 06 year: 2022 text: 2022-06-28 day: 28 |
PublicationDecade | 2020 |
PublicationTitle | Frontiers in molecular biosciences |
PublicationYear | 2022 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Zhou (B47) 2021; 1876 Zhang (B44) 2017; 23 Blass (B3) 2021; 18 Li (B14) 2020; 39 Brehm (B39) 2015; 37 Schaefer (B26) 2019; 29 Lei (B13) 2020; 470 Strickler (B32) 2021; 27 Yi (B41) 2019; 56 Zhang (B45) 2020; 17 Wang (B40) 2020; 18 Prasad (B23) 2020; 1866 Braga (B4) 2020; 21 Primeaux (B24) 2022; 39 Toulis (B35) 2016; 1449 Yun (B43) 2015; 9 Conte (B7) 2018; 8 Pan (B20) 2015; 34 Thiagalingam (B34) 2002; 14 Chopra (B5) 2020; 11 Su (B33) 2019; 36 Hou (B9) 2020; 8 Baretti (B2) 2018; 189 Turnbull (B36) 2017; 550 Visani (B38) 2021; 27 Lange (B12) 2022; 82 Perez‐Oliva (B22) 2015; 34 Liu (B16) 2019; 846 McGranahan (B19) 2017; 168 An (B1) 2022; 21 Sowa (B30) 2009; 138 Jingjing (B11) 2018; 7 Hoppe (B8) 2018; 110 Tyagi (B37) 2021; 48 Malta (B18) 2018; 173 Huang (B10) 2019; 7 Seiberlich (B27) 2012; 1823 Smillie (B29) 2018; 53 Zhao (B46) 2021; 11 Li (B15) 2021; 22 Qi (B25) 2015; 52 Stevenson (B31) 2007; 26 Peng (B21) 2019; 18 Collins (B6) 2017; 474 Malhotra (B17) 2013; 14 Yu (B42) 2021; 2021 Sharma (B28) 2021; 22 |
References_xml | – volume: 18 start-page: 215 year: 2021 ident: B3 article-title: Advances in the Development of Personalized Neoantigen-Based Therapeutic Cancer Vaccines publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-00460-2 – volume: 2021 start-page: 1 year: 2021 ident: B42 article-title: Methylation Modification, Alternative Splicing, and Noncoding RNA Play a Role in Cancer Metastasis through Epigenetic Regulation publication-title: BioMed Res. Int. doi: 10.1155/2021/4061525 – volume: 1866 start-page: 165424 year: 2020 ident: B23 article-title: Cancer Cells Stemness: A Doorstep to Targeted Therapy publication-title: Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. doi: 10.1016/j.bbadis.2019.02.019 – volume: 27 start-page: 1236 year: 2021 ident: B32 article-title: Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better? publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-20-3054 – volume: 21 start-page: 14 year: 2022 ident: B1 article-title: The Role of m6A RNA Methylation in Cancer Metabolism publication-title: Mol. Cancer doi: 10.1186/s12943-022-01500-4 – volume: 53 start-page: 231 year: 2018 ident: B29 article-title: Complexities of Post-transcriptional Regulation and the Modeling of ceRNA Crosstalk publication-title: Crit. Rev. Biochem. Mol. Biol. doi: 10.1080/10409238.2018.1447542 – volume: 474 start-page: 1127 year: 2017 ident: B6 article-title: Chemical Approaches to Targeted Protein Degradation through Modulation of the Ubiquitin-Proteasome Pathway publication-title: Biochem. J. doi: 10.1042/BCJ20160762 – volume: 22 start-page: 11971 year: 2021 ident: B28 article-title: Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms222111971 – volume: 846 start-page: 1 year: 2019 ident: B16 article-title: Auranofin Lethality to Prostate Cancer Includes Inhibition of Proteasomal Deubiquitinases and Disrupted Androgen Receptor Signaling publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2019.01.004 – volume: 21 start-page: 8855 year: 2020 ident: B4 article-title: LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms21228855 – volume: 56 start-page: 325 year: 2019 ident: B41 article-title: Biallelic Mutations in USP45, Encoding a Deubiquitinating Enzyme, Are Associated with Leber Congenital Amaurosis publication-title: J. Med. Genet. doi: 10.1136/jmedgenet-2018-105709 – volume: 8 start-page: 14375 year: 2018 ident: B7 article-title: USP45 and Spindly Are Part of the Same Complex Implicated in Cell Migration publication-title: Sci. Rep. doi: 10.1038/s41598-018-32685-8 – volume: 173 start-page: 338 year: 2018 ident: B18 article-title: Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation publication-title: Cell doi: 10.1016/j.cell.2018.03.034 – volume: 9 start-page: 1834 year: 2015 ident: B43 article-title: Ubiquitin Specific Protease 4 Positively Regulates the WNT/beta-catenin Signaling in Colorectal Cancer publication-title: Mol. Oncol. doi: 10.1016/j.molonc.2015.06.006 – volume: 39 start-page: 391 year: 2022 ident: B24 article-title: Role of CD44 Isoforms in Epithelial-Mesenchymal Plasticity and Metastasis publication-title: Clin. Exp. Metastasis doi: 10.1007/s10585-022-10146-x – volume: 1823 start-page: 2057 year: 2012 ident: B27 article-title: The Small Molecule Inhibitor PR-619 of Deubiquitinating Enzymes Affects the Microtubule Network and Causes Protein Aggregate Formation in Neural Cells: Implications for Neurodegenerative Diseases publication-title: Biochim. Biophys. Acta (BBA) - Mol. Cell Res. doi: 10.1016/j.bbamcr.2012.04.011 – volume: 27 start-page: 2710 year: 2021 ident: B38 article-title: Molecular Alterations in Pancreatic Tumors publication-title: World J Gastroenterol. doi: 10.3748/wjg.v27.i21.2710 – volume: 29 start-page: 336 year: 2019 ident: B26 article-title: Regulation of Glioma Cell Invasion by 3q26 Gene Products PIK3CA, SOX2 and OPA1 publication-title: Brain Pathol. doi: 10.1111/bpa.12670 – volume: 23 start-page: 6279 year: 2017 ident: B44 article-title: Tumor Purity as an Underlying Key Factor in Glioma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-2598 – volume: 138 start-page: 389 year: 2009 ident: B30 article-title: Defining the Human Deubiquitinating Enzyme Interaction Landscape publication-title: Cell doi: 10.1016/j.cell.2009.04.042 – volume: 14 start-page: 65 year: 2002 ident: B34 article-title: Loss of Heterozygosity as a Predictor to Map Tumor Suppressor Genes in Cancer: Molecular Basis of its Occurrence publication-title: Curr. Opin. Oncol. doi: 10.1097/00001622-200201000-00012 – volume: 189 start-page: 45 year: 2018 ident: B2 article-title: DNA Mismatch Repair in Cancer publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2018.04.004 – volume: 14 start-page: 840 year: 2013 ident: B17 article-title: Chromosomal Structural Variations during Progression of a Prostate Epithelial Cell Line to a Malignant Metastatic State Inactivate the NF2, NIPSNAP1, UGT2B17, and LPIN2 Genes publication-title: Cancer Biol. Ther. doi: 10.4161/cbt.25329 – volume: 52 start-page: 710 year: 2015 ident: B25 article-title: ceRNA in Cancer: Possible Functions and Clinical Implications publication-title: J. Med. Genet. doi: 10.1136/jmedgenet-2015-103334 – volume: 37 start-page: 323 year: 2015 ident: B39 article-title: Dysfunction in Protein Clearance by the Proteasome: Impact on Autoinflammatory Diseases publication-title: Seminars in Immunopathology doi: 10.1007/s00281-015-0486-4 – volume: 470 start-page: 126 year: 2020 ident: B13 article-title: Immune Cells within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy publication-title: Cancer Lett. doi: 10.1016/j.canlet.2019.11.009 – volume: 11 start-page: 2662 year: 2020 ident: B5 article-title: Homologous Recombination DNA Repair Deficiency and PARP Inhibition Activity in Primary Triple Negative Breast Cancer publication-title: Nat. Commun. doi: 10.1038/s41467-020-16142-7 – volume: 550 start-page: 481 year: 2017 ident: B36 article-title: Molecular Basis of USP7 Inhibition by Selective Small-Molecule Inhibitors publication-title: Nature doi: 10.1038/nature24451 – volume: 1876 start-page: 188609 year: 2021 ident: B47 article-title: The RNA m6A Writer METTL14 in Cancers: Roles, Structures, and Applications publication-title: Biochim. Biophys. Acta (BBA) - Rev. Cancer doi: 10.1016/j.bbcan.2021.188609 – volume: 168 start-page: 613 year: 2017 ident: B19 article-title: Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future publication-title: Cell doi: 10.1016/j.cell.2017.01.018 – volume: 1449 start-page: 85 year: 2016 ident: B35 article-title: Combining Zebrafish and Mouse Models to Test the Function of Deubiquitinating Enzyme (Dubs) Genes in Development: Role of USP45 in the Retina publication-title: Methods Mol. Biol. doi: 10.1007/978-1-4939-3756-1_3 – volume: 8 start-page: 339 year: 2020 ident: B9 article-title: Prognostic Significance of Mutant-Allele Tumor Heterogeneity in Uterine Corpus Endometrial Carcinoma publication-title: Ann. Transl. Med. doi: 10.21037/atm.2020.02.136 – volume: 36 start-page: 139 year: 2019 ident: B33 article-title: The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.06.009 – volume: 22 start-page: 986 year: 2021 ident: B15 article-title: Molecular Mechanisms of DUBs Regulation in Signaling and Disease publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms22030986 – volume: 18 start-page: 112 year: 2020 ident: B40 article-title: The Deubiquitinase USP22 Regulates PD-L1 Degradation in Human Cancer Cells publication-title: Cell Commun. Signal doi: 10.1186/s12964-020-00612-y – volume: 11 start-page: 6119 year: 2021 ident: B46 article-title: Automated Assessment of DNA Ploidy, Chromatin Organization, and Stroma Fraction to Predict Prognosis and Adjuvant Therapy Response in Patients with Stage II Colorectal Carcinoma publication-title: Am. J. Cancer Res. – volume: 26 start-page: 976 year: 2007 ident: B31 article-title: The Deubiquitinating Enzyme USP2a Regulates the P53 Pathway by Targeting Mdm2 publication-title: EMBO J. doi: 10.1038/sj.emboj.7601567 – volume: 18 start-page: 128 year: 2019 ident: B21 article-title: Neoantigen Vaccine: an Emerging Tumor Immunotherapy publication-title: Mol. Cancer doi: 10.1186/s12943-019-1055-6 – volume: 34 start-page: 3957 year: 2015 ident: B20 article-title: USP37 Directly Deubiquitinates and Stabilizes C-Myc in Lung Cancer publication-title: Oncogene doi: 10.1038/onc.2014.327 – volume: 34 start-page: 326 year: 2015 ident: B22 article-title: USP45 Deubiquitylase Controls ERCC1-XPF Endonuclease-Mediated DNA Damage Responses publication-title: EMBO J. doi: 10.15252/embj.201489184 – volume: 82 start-page: 15 year: 2022 ident: B12 article-title: Deubiquitinases: From Mechanisms to Their Inhibition by Small Molecules publication-title: Mol. Cell doi: 10.1016/j.molcel.2021.10.027 – volume: 48 start-page: 102194 year: 2021 ident: B37 article-title: Redox Regulation of DUBs and its Therapeutic Implications in Cancer publication-title: Redox Biol. doi: 10.1016/j.redox.2021.102194 – volume: 17 start-page: 807 year: 2020 ident: B45 article-title: The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-Infiltrating Immune Cells and Their Therapeutic Implications publication-title: Cell Mol. Immunol. doi: 10.1038/s41423-020-0488-6 – volume: 39 start-page: 2258 year: 2020 ident: B14 article-title: He Wnt/Beta-Catenin/VASP Positive Feedback Loop Drives Cell Proliferation and Migration in Breast Cancer publication-title: Oncogene doi: 10.1038/s41388-019-1145-3 – volume: 7 start-page: 1580 year: 2019 ident: B10 article-title: USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-18-0910 – volume: 7 start-page: 4004 year: 2018 ident: B11 article-title: Deubiquitination and Stabilization of Programmed Cell Death Ligand 1 by Ubiquitin-Specific Peptidase 9, X-Linked in Oral Squamous Cell Carcinoma publication-title: Cancer Med. doi: 10.1002/cam4.1675 – volume: 110 start-page: 704 year: 2018 ident: B8 article-title: Biomarkers for Homologous Recombination Deficiency in Cancer publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djy085 |
SSID | ssj0001503764 |
Score | 2.2480476 |
Snippet | Background:
Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of... Background: Deubiquitinating enzymes specifically removes ubiquitin molecules from ubiquitin-tagged target proteins, thereby inhibiting the degradation of... |
SourceID | doaj pubmedcentral proquest crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 886904 |
SubjectTerms | deubiquitinating enzyme Molecular Biosciences pan-cancer analysis TCGA (The Cancer Genome Atlas Program) tumor immunotherapy USP45 |
SummonAdditionalLinks | – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEB3SLYVeSpO0dPuFAj0VXLSSbMuHUtrQEAL7QdOF3IQkS01gsVvvbmj-fWdsb6gh5JSTwZawNaOH3kjjNwAfrPAFzyircZJniXKRJ4VVPNHeCy9pp8HS1sB0lp0u1dlFerEHu_JWvQHXd4Z2VE9q2aw-_f1z8wUB_5kiTlxv0QP1ymGoJwS6HaM99Qge48KUE06nPdvvfhrmCCfVnW3e3XOwOrUi_gPmOcyb_G8hOnkOz3oGyb52Lt-HvVAdwJOupuTNIcwJ4U247BLT2U50hP0I18gJ12x5vlAps2tm2ay-Diu22G5a8W82r3yN0ymwq4otbJUc04RoXsDy5PvP49Okr5qQeKXEJkEMRll47RCrqc11aqPPWqmtEq-FlhYZQ6nJE1Ej_dA6zW0qeDnJHN4p5UsYVXUVXgHzEcMdl09ixqWSZbDaFTxGqbBXFqIbA99Zy_heUpwqW6wMhhZkYNMa2JCBTWfgMXy87fK709O4r_E3csFtQ5LCbm_UzS_TI8vwEJXypY84KqWtsDIgRStzl1vkj1aO4WjnQIPQofMQW4V6uzYiK1pxIsHHkA88O3jj8El1ddmKcBfI-4qJeP0Qn_gGntKoKQNN6Lcw2jTb8A65zsa9b2fwP2Ti_dU priority: 102 providerName: Scholars Portal |
Title | Comprehensive Analysis Reveals USP45 as a Novel Putative Oncogene in Pan-Cancer |
URI | https://www.proquest.com/docview/2691047820 https://pubmed.ncbi.nlm.nih.gov/PMC9273912 https://doaj.org/article/0ef44cdcf75d48a2a3e159d7b7a009a3 |
Volume | 9 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1JS8QwFA4iCF7EFceNCJ6EYiZN2-SogyLCLKgDcwtJmqAwtDIb-O99SWaG6UUvXlpIE5q-hXwvef0eQjeKGkFyn9XYLvKEaUcSoRhJuDHUpH6nQfmtgW4vfx6yl1E22ij15XPCIj1wFNwdsY4xUxpXZCXjiqrUwgpcFrpQAA9U4PmENW8jmIr_BxPwHBaPMSEKE6CmeqwhHqQUbANCQtZYiAJffwNkNlMkN9acp320twSL-D5O8gBt2eoQ7cTykd9HqO-deWI_Yg46XvGL4Fe7APg3xcO3AcuwmmKFe_XCjvFgPgs837hfmRosx-LPCg9UlXS87ifHaPj0-N55TpYFEhLDGJ0l4G4uFYZrcMtMFTxTzuSBVauEu-CpAnBQci90xwFpcJ4VKqOkbOcaWsr0BG1XdWVPETYOIhtdtF1OUpaWVnEtiHMpg1G5dbqFyEpa0izZw30Ri7GEKMILWAYBSy9gGQXcQrfrIV-ROuO3zg9eBeuOnvU6NIAtyKUtyL9soYWuVwqU4CX-6ENVtp5PJc1F4CGipIWKhmYbb2w-qT4_At-2AIgn2vTsP6Z4jnb9V_tkM8ov0PZsMreXAGtm-ipYMFy7jP8AMcr2tQ |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comprehensive+Analysis+Reveals+USP45+as+a+Novel+Putative+Oncogene+in+Pan-Cancer&rft.jtitle=Frontiers+in+molecular+biosciences&rft.au=Kai+Li&rft.au=Kai+Li&rft.au=Qian+Wang&rft.au=Qian+Wang&rft.date=2022-06-28&rft.pub=Frontiers+Media+S.A&rft.eissn=2296-889X&rft.volume=9&rft_id=info:doi/10.3389%2Ffmolb.2022.886904&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_0ef44cdcf75d48a2a3e159d7b7a009a3 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-889X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-889X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-889X&client=summon |